Streetbeat News

Stock Prices

TSLA

Tesla, Inc. is projected to reach a stock price of $424 by year-end, driven by increased production and strong demand for Model 3/Y, as well as potential advancements in full self-driving technology.

Portfolio Pulse from

December 11, 2024 | 5:15 pm

DLR

Digital Realty (DLR) is expected to experience growth due to strong data center demand and strategic investments, despite facing a competitive market and asset concentration challenges.

Portfolio Pulse from

December 11, 2024 | 5:15 pm

AIXI

Pomerantz Law Firm has filed a class action lawsuit against Xiao-I Corporation (NASDAQ:AIXI) and certain officers and directors. The lawsuit is on behalf of investors who purchased Xiao-I securities during the specified class period, alleging issues related to the company's IPO.

Portfolio Pulse from

December 11, 2024 | 5:15 pm

PACS

Rosen Law Firm is urging investors of PACS Group Inc. to secure legal counsel before the January 13, 2025 deadline in a securities class action. This involves those who purchased PACS stock during its IPO, SPO, or within the specified class period.

Portfolio Pulse from

December 11, 2024 | 5:15 pm

TMC

Pomerantz Law Firm has filed a class action lawsuit against TMC the metals company Inc. and certain officers, alleging violations of federal securities laws. The lawsuit is on behalf of investors who acquired TMC securities between May 12, 2023, and March 25, 2024.

Portfolio Pulse from

December 11, 2024 | 5:15 pm

AEHR

Pomerantz Law Firm has filed a class action lawsuit against Aehr Test Systems, Inc. and certain officers, alleging violations of federal securities laws. The lawsuit is on behalf of investors who acquired Aehr securities between January 9, 2024, and March 24, 2024.

Portfolio Pulse from

December 11, 2024 | 5:15 pm

XRX

Levi & Korsinsky has notified investors of Xerox Holdings Corporation about a class action lawsuit. Investors who suffered losses can learn about potential recovery under federal securities laws.

Portfolio Pulse from

December 11, 2024 | 5:15 pm

VRTX

Vertex Pharmaceuticals remains a strong buy despite a recent sell-off. The company's CF franchise, led by TRIKAFTA, continues to perform well, and the upcoming Vanzacaftor therapy is expected to drive further growth. Additionally, the CRISPR-based therapy Casgevy shows promising potential with multi-billion-dollar revenue projections.

Portfolio Pulse from

December 11, 2024 | 5:15 pm

RYAAY

The International Air Transport Association (IATA) forecasts that passenger volumes will exceed 5 billion by 2025, driven by low fuel costs. This optimistic outlook suggests potential growth for airline stocks.

Portfolio Pulse from

December 11, 2024 | 5:00 pm

AAPL

AVGO

Broadcom's stock rose significantly today following reports of a collaboration with Apple on an AI chip.

Portfolio Pulse from

December 11, 2024 | 5:00 pm